The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.
RecruitingNot applicableNCT07000409
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To investigate the effectiveness of ultra-Sound guided Erector spinae block (ESB) with Betamethasone as an adjuvant to standard medical protocol in the management of truncal chronic post herpetic neuralgia.
Study details
- Official title
- The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia, a Prospective Randomized Controlled Study.
- Conditions
- Postherpetic Neuralgia
- Chronic Pain
- Ultrasound Guidance
- Erector Spinae Plane Block
- Betamethasone
- Interventions
- Other: Medical management regimen
- Other: Erector spinae plane (ESP) block
- Sponsor
- Cairo University
- Start date
- 2025-05-01
- Primary completion
- 2025-12-30
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients age between 18 and 75. * Patients with American Society of Anesthesiologists (ASA) II and III status. * Patients diagnosed with truncal chronic post herpetic neuralgia( neuropathic pain persistent for more than 3 months from the onset of rash appearance ) Exclusion Criteria: * Patients unable to comprehend the informed consent. * Patients on long term opioid regimens. * Patients with impairment in hepatic (Alanine aminotransferase (ALT) \>50 U/L, and/or Aspartate aminotransferase (AST): \>45 U/L) or renal functions( creatinine level ≥1.5 mg/dL) * Patients on anti-coagulation regimens. * Patients with coagulation abnormalities (i.e. international normalized ratio (INR) ≥1.5 and/or platelets ≤50000) * Local infection in the site of the block. * Patients with body mass index (BMI) \> 35.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07000409